tiprankstipranks
Advertisement
Advertisement

VRTX Stock Latest News

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
TipRanks NewswireNuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
3d ago
NVS
CRNX
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
PremiumTipRanks Newswire
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
4d ago
PTN
CRNX
Vertex’s VX-581 Dose Escalation Trial: A Fresh Signal on Cystic Fibrosis Pipeline Strength
PremiumCompany Announcements
Vertex’s VX-581 Dose Escalation Trial: A Fresh Signal on Cystic Fibrosis Pipeline Strength
10d ago
VRTX
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?
PremiumTipRanks Newswire
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?
11d ago
AZN
LLY
Vertex Pharmaceuticals price target raised to $585 from $545 at UBS
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $585 from $545 at UBS
13d ago
VRTX
Vertex Pharmaceuticals price target raised to $560 from $542 at Truist
PremiumThe FlyVertex Pharmaceuticals price target raised to $560 from $542 at Truist
13d ago
VRTX
Vertex Pharmaceuticals price target raised to $600 from $598 at BofA
Premium
The Fly
Vertex Pharmaceuticals price target raised to $600 from $598 at BofA
13d ago
VRTX
Vertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology Upside
Premium
Ratings
Vertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology Upside
13d ago
VRTX
3 Trending Stocks to Watch, According to Analysts – 7/9/2026
PremiumMarket News
3 Trending Stocks to Watch, According to Analysts – 7/9/2026
17d ago
XOM
CRNX
Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained
PremiumRatings
Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained
17d ago
VRTX
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
PremiumTipRanks Newswire
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
17d ago
LLY
ABBV
Crinetics downgraded to Hold from Buy at TD Cowen
PremiumThe Fly
Crinetics downgraded to Hold from Buy at TD Cowen
19d ago
CRNX
VRTX
Midday Fly By: Wall Street starts coverage of SpaceX with bullish ratings
PremiumThe FlyMidday Fly By: Wall Street starts coverage of SpaceX with bullish ratings
19d ago
AAL
LMT
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
Premium
The Fly
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
19d ago
ASND
BCRX
Morning Movers: Lam Research and Micron dip after Samsung quarterly results
Premium
The Fly
Morning Movers: Lam Research and Micron dip after Samsung quarterly results
19d ago
MU
Vertex–Crinetics Deal Broadens Endocrinology Portfolio but Integration Uncertainties and Valuation Keep Rating at Hold, Price Target Unchanged at $436
PremiumRatings
Vertex–Crinetics Deal Broadens Endocrinology Portfolio but Integration Uncertainties and Valuation Keep Rating at Hold, Price Target Unchanged at $436
19d ago
VRTX
Vertex adds ‘genuine fifth commercial pillar’ with deal, says H.C. Wainwright
PremiumThe Fly
Vertex adds ‘genuine fifth commercial pillar’ with deal, says H.C. Wainwright
19d ago
CRNX
VRTX
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
19d ago
VRTX
Vertex Pharmaceuticals price target raised to $350 from $330 at Baird
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $350 from $330 at Baird
19d ago
VRTX
Crinetics price target raised to $85 from $62 at Baird
PremiumThe FlyCrinetics price target raised to $85 from $62 at Baird
19d ago
CRNX
VRTX
Vertex Pharmaceuticals to Acquire Crinetics in Cash Merger
Premium
Company Announcements
Vertex Pharmaceuticals to Acquire Crinetics in Cash Merger
19d ago
8K
VRTX
Crinetics downgraded to Perform from Outperform at Oppenheimer
Premium
The Fly
Crinetics downgraded to Perform from Outperform at Oppenheimer
19d ago
CRNX
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >